PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™, and the companies leading the charge in developing new, safe and effective treatments for liver disease.
- NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™, and the companies leading the charge in developing new, safe and effective treatments for liver disease.
- The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease, a leading cause of liver-related mortality that affects between six and eight million adults in the US.
- Experts believe this overhaul may be the rebrand that liver disease needs to generate better clinical results for specific patient populations.
- PRISM MarketView takes a closer look at five of our top picks for delivering the next potential treatments for the liver disease patient population, including Inventiva , NeuroBo Pharmaceuticals , and Better Therapeutics .